Global Infectious Diseases & Vaccines Team – Clinical Operations Experts

The complex nature of infectious diseases requires a full-service CRO with deep expertise and operational strategies to successfully execute ID&V clinical trials. Our global team of ID&V experts takes a collaborative approach to support end-to-end development of your pipeline. Leveraging global, full-service capabilities, Medpace excels in driving all study phases including real-world evidence trials and a variety of study strategies, including adaptive design. We have successfully supported a wide range of products covering microbiome, bacteriophage, monoclonal antibodies, small and large molecules, and all routes of administration. In the past 7 years, Medpace ID&V experts have contributed to:

Our holistic approach integrates cross-functional expertise across operational, regulatory, medical, safety, data management, and biostats throughout the lifecycle of the trial to reduce risk and progress your development plan. With offices strategically located around the world, Medpace offers global engagement to navigate languages, cultures, and global clinical and regulatory environments. Our strong relationships with investigators and sites enable fast start-up timelines and effective patient-centric recruitment efforts.

Video Series: Spotlight on Global Clinical Operations Experts

In the following video series, Medpace experts across North America, Europe, Latin America, and Asia Pacific will explore how our ID&V team optimizes local and regional aspects to enhance the success of your global trial and accelerate your path to approval.

An Industry Leader in ID&V Clinical Development

Achieve quality results, meet deadlines, and maximize efficiencies by partnering with a full-service CRO that excels in designing and executing clinical research in antivirals, antibacterials, antifungals and vaccines. Extensive experience gives our medical, regulatory, and operational staff a thorough understanding of the complexities of ID&V trials from the perspectives of all the stakeholders involved in developing treatments for new and re-emerging infectious diseases.